Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TMEM206 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | ATXN7L3B | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | SNRPA | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
mRNA | UGT3A2 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
mRNA | BLMH | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
mRNA | ATP5H | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | C16orf95 | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |
mRNA | KCMF1 | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | DLX5 | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
mRNA | LINC00116 | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |